Idorsia Archives

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. The trial recruited 930 adult patients with insomnia. The company used a technique called polysomnography to measure the time taken to fall asleep and sleep […]

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

cardiology astrazeneca novartis cardiovascular disease

News and Trends 5 Sep 2019

Top Cardiology Biotech News from the ESC Conference 2019

Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […]

September 5, 2019 - 4 minutesmins - By Jonathan Smith

Best in Biotech 21 May 2019

The Top 20 Women in Leading Biotech Roles in Europe

The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […]

May 21, 2019 - 12 minutesmins - By Jonathan Smith

More News! 18 Jun 2018

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […]

June 18, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […]

May 16, 2018 - 3 minutesmins - By Alexander Burik

Best in Biotech 8 Mar 2018

Say Hello to the Top 14 Entrepreneurial Women in European Biotech

Today, March 8, is international women’s day. To celebrate the achievements of women we’re revisiting our list of the women that have founded some of the hottest biotechs in Europe. Once upon a time, you would have been hard pushed to find a woman in a senior position at a top biotech – now, they […]

March 8, 2018 - 8 minutesmins - By Alex Dale

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […]

December 4, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Idorsia

The Billion-Euro European Biotech Companies in 2022

A Year to Remember: The Biggest European Biotech News in 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

Top Cardiology Biotech News from the ESC Conference 2019

The Top 20 Women in Leading Biotech Roles in Europe

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Say Hello to the Top 14 Entrepreneurial Women in European Biotech

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!